Preferred Label : Therapeutic Cancer Vaccine ATP150;
NCIt definition : A self-adjuvanted chimeric recombinant protein priming vaccine, based on the self-adjuvanting
KISIMA immunization platform, composed of three components: the 42 residue fragment
Z12, a cell penetrating peptide (CPP) derived from the ZEBRA protein transduction
domain, a toll-like receptor (TLR) peptide agonist as an adjuvant and a chimeric cargo,
a multiple antigenic domain (MAD; MultiE), that contains an as of yet not disclosed
amount of major histocompatibility class (MHC)-restricted peptides derived from as
of yet undisclosed tumor-associated antigens (TAAs) that are specific for pancreatic
cancer patients, with potential immunomodulating and antineoplastic activities. Upon
administration of ATP150, the Z12 moiety targets, binds to and penetrates antigen-presenting
cells (APCs), specifically dendritic cells (DCs) and promotes the loading of the epitopes
into the DCs and transports antigenic cargoes into both endosomal and cytosolic compartments.
Upon processing and antigen presentation by MHC II and I, the immune system is stimulated
and activates specific CD4 and CD8 T-cells, respectively, against the multi-epitopes
specific for pancreatic adenocarcinoma cells, thereby killing the tumor cells.;
Molecule name : ATP-150; ATP 150;
NCI Metathesaurus CUI : CL1906569;
Origin ID : C199670;
UMLS CUI : C5854455;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
